PARP1 and hepatocellular carcinoma: Based on these findings, we propose the use of a CP/MH combination as a promising therapeutic strategy to enhance the efficacy of conventional chemotherapeutic drugs, thereby improving clinical outcomes in HCC patients by targeting the PARP1/HMGB1 pathway of autophagy.